Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease.

Li X, Deng R, He W, Liu C, Wang M, Young J, Meng Z, Du C, Huang W, Chen L, Chen Y, Martin P, Forman S, Zeng D.

J Immunol. 2012 Jan 15;188(2):724-34. doi: 10.4049/jimmunol.1102630.

2.

Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.

Kato K, Cui S, Kuick R, Mineishi S, Hexner E, Ferrara JL, Emerson SG, Zhang Y.

Biol Blood Marrow Transplant. 2010 Jun;16(6):751-71. doi: 10.1016/j.bbmt.2010.01.012.

3.

Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation.

Ueki S, Castellaneta A, Yoshida O, Ozaki K, Zhang M, Kimura S, Isse K, Ross M, Shao L, Stolz DB, Thomson AW, Demetris AJ, Geller DA, Murase N.

Hepatology. 2011 Jul;54(1):216-28. doi: 10.1002/hep.24360.

4.

Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity.

Phares TW, Ramakrishna C, Parra GI, Epstein A, Chen L, Atkinson R, Stohlman SA, Bergmann CC.

J Immunol. 2009 May 1;182(9):5430-8. doi: 10.4049/jimmunol.0803557.

5.

Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease.

Zhao F, Zhang Y, Wang H, Jin M, He S, Shi Y, Guo Y, Zhang Y.

Blood. 2011 Feb 3;117(5):1723-33. doi: 10.1182/blood-2010-04-281659.

6.

Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM).

Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY, Mak TW, Serody JS, Blazar BR.

Blood. 2005 Apr 15;105(8):3372-80.

7.

Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.

Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Korngold R, Vallera DA.

J Immunol. 1996 Oct 15;157(8):3250-9.

PMID:
8871619
8.

PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.

Koestner W, Hapke M, Herbst J, Klein C, Welte K, Fruehauf J, Flatley A, Vignali DA, Hardtke-Wolenski M, Jaeckel E, Blazar BR, Sauer MG.

Blood. 2011 Jan 20;117(3):1030-41. doi: 10.1182/blood-2010-04-283119.

9.

Inhibition of graft-versus-host disease by double-negative regulatory T cells.

Young KJ, DuTemple B, Phillips MJ, Zhang L.

J Immunol. 2003 Jul 1;171(1):134-41.

10.

Donor CD8+ T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody.

Zhang C, Lou J, Li N, Todorov I, Lin CL, Cao YA, Contag CH, Kandeel F, Forman S, Zeng D.

J Immunol. 2007 Jan 15;178(2):838-50.

12.

Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease.

Rotolo JA, Stancevic B, Lu SX, Zhang J, Suh D, King CG, Kappel LW, Murphy GF, Liu C, Fuks Z, van den Brink MR, Kolesnick R.

Blood. 2009 Oct 22;114(17):3693-706. doi: 10.1182/blood-2008-11-191148.

13.

The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.

Dey B, Yang YG, Preffer F, Shimizu A, Swenson K, Dombkowski D, Sykes M.

Transplantation. 1999 Jul 15;68(1):141-9.

PMID:
10428282
15.

CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells.

Liu K, Anthony BA, Yearsly MM, Hamadani M, Gaughan A, Wang JJ, Devine SM, Hadley GA.

PLoS One. 2011;6(7):e21968. doi: 10.1371/journal.pone.0021968.

16.

APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease.

Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A, Giannola D, Emerson SG.

J Immunol. 2002 Dec 15;169(12):7111-8.

17.

Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.

Du W, Leigh ND, Bian G, O'Neill RE, Mei L, Qiu J, Chen GL, Hahn T, Liu H, McCarthy PL, Cao X.

J Immunol. 2015 Nov 1;195(9):4514-23. doi: 10.4049/jimmunol.1500668.

18.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611.

19.

Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.

Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE.

J Immunol. 1996 Dec 1;157(11):4811-21.

PMID:
8943383
20.

Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.

Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG.

J Immunol. 2005 Mar 1;174(5):3051-8.

Supplemental Content

Support Center